Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation. Issue 1 (25th February 2021)

• Record Type: Journal Article
• Authors: Donigian, Sara; Whiteway, Susan L.; Hipp, Sean J.; Lybeck, Dustin; Clark, Rebecca O.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 44:Issue 1(2022)
• Page Start: e268
• Page End: e271
• Publication Date: 2021-02-25
• Subjects: giant cell -- bone -- sarcoma -- KRAS; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002112
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Malignant giant cell tumor of bone (GCTB) is a rare, aggressive, sarcoma occurring in adolescent and young adults. It is characterized by the presence of multinucleated giant cells and an aggressive clinical course. Because of the rarity of this tumor, no standard therapies have been identified. Current treatment regimens often include osteosarcoma chemotherapy protocols. We present a case of a malignant GCTB with a KRAS G12V mutation. This mutation is a known oncogenic driver that has not previously been reported on patients with malignant GCTB.